January 25, 2021


The MarketWatch News Department was not involved in the creation of this content.

Dec 01, 2020 (CDN Newswire via Comtex) —
Global Automotive Transmission Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025 published on MarketQuest.biz provides an in-depth analysis of industry- and economy-wide database for businesses that could offer profitable development for players in this market. The report gives a detailed study of global Automotive Transmission market size, share, and dynamics. In this research, analysts have illustrated market trends. The report has covered major key players of the market which are also profiled on the basis of business strategies, financial weaknesses, and strengths, and recent development. The report analyzes rapidly changing market scenarios and initial and future assessment of the market. The document offers a special assessment of collaboration, partnership, acquisition, and new product launch of the major key players.

The report focuses on primary and secondary drivers, market share, leading segments, and regional analysis as well as upcoming and trending innovations. The report contains a comprehensive database on future market estimation based on historical data analysis. Then information & analysis pertaining to the global Automotive Transmission market segment and forecasts from 2020-2025 has been given. Reliable predictions based on value and volume is provided to help market players to get deep insights into the overall industry. Further, the report estimates cost and pricing operating in specific geographies. Also graphs, charts are used to support the data format for a clear understanding of facts and figures.

NOTE: Our report highlights the major issues and hazards that companies might come across due to the unprecedented outbreak of COVID-19.

DOWNLOAD FREE SAMPLE REPORT:https://www.marketquest.biz/sample-request/33374

Global Automotive Transmission market report also delivers information such as company profiles, product picture and specification, capacity, production, price, cost, revenue, development trends, and marketing channels. Additionally, the manufacturers’ data covered in this report includes shipment, price, revenue, gross profit, interview record, business distribution. Regional development status is explained with respect to market size, volume, and value, as well as price data.

Top players of the global Automotive Transmission market are studied: ASIN, Magna, Getrag, ZF, MOBIS, Jatco, GM, Honda, Volkswagen, SAIC, Borgwarner, Chongqing Tsingshan, Eaton Corporation, Zhejiang Wanliyang, Allison Transmission, Continental

The report provides a forecast (2020-2025) assessed based on how the market is predicted to grow in major regions like: North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, etc.), Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa)

Global market size & share, by-products: MT, AT, AMT, CVT, DCT

Global market size & share, applications: Passenger Vehicle, Commercial Vehicle

ACCESS FULL REPORT:https://www.marketquest.biz/report/33374/global-automotive-transmission-market-2020-by-manufacturers-regions-type-and-application-forecast-to-2025

Reasons to Buy This Report:

  • To get important competitor information, analysis, and insights to formulate effective R&D strategies
  • To recognize emerging players along with product portfolio and create effective counter-strategies to gain competitive advantage
  • To develop tactical initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions

logo, company name

© Marketwatch


Shares of China Automotive Systems Inc. skyrocketed 96.9% on heavy volume, to pace all premarket gainers on Monday, after the Wuhan, China-based company said so far this yaer it has shipped about 120,000 of its electric power-steering products for use in electric vehicles made in China. Trading volume swelled to 3.9 million share, compared with the full-day average of about 171,000 shares. The company said it expects to sell over 140,000 units of its steering products this year, and about 200,000 units next year. Among the electric vehicle makers the company sells to are SUV and truck maker Great Wall Motors, state-owned auto maker Chery Automobile, Beijing Auto, JAC Motors and Dongfeng Auto and Hozon Auto. China Automotive noted that sales of China-made EVs about doubled from a year ago to 144,000 units in October, and China’s government has set and EV car target of 25% of all new cars by 2025. China Automotive’s stock has run up 43.5% over the past three months through Friday, while the iShares MSCI China ETF has gained 6.7% and the S&P 500 has edged up 3.7%.


Load Error

Continue Reading

Source Article


Update, Saturday 11:25 a.m.: Police in Bartlesville identified the man shot by officers as 25-year-old Tyler Scott Thomas Rollins. A news release indicates that Rollins is listed in what has been described as stable condition at a Tulsa hospital.  

The story as it appeared in Saturday’s print version is below. 

Bartlesville police officers shot a man Friday evening after he reportedly pulled a gun while fleeing on foot.

The shooting happened about 7 p.m. Friday near the Casey’s General Store at the intersection of Madison and Adams boulevards, according to a news release from the Bartlesville Police Department.

Officers made contact with a man reportedly wanted on two felony warrants at the convenience store’s gas pumps and observed him in a black Ford Edge reported stolen Thursday. As officers approached, the man fled on foot and during the foot chase pulled a firearm on the two pursuing officers, according to a news release.

Both officers shot the suspect, who was taken to a Bartlesville hospital before being transferred to St. John’s Medical Center in Tulsa. No information was available Friday night on his condition.

Neither the man nor officers who shot him have been identified as of Friday night, and the Oklahoma State Bureau of Investigation is handling the investigation, according to a news release.

Source Article


CAMBRIDGE, England & BOSTON–(BUSINESS WIRE)–Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced progress updates across its wholly-owned and partnered programs in oncology and non-oncology indications.

“We and our partners have recently achieved important progress in the advancement of our pipeline that we believe could catalyze the next stage of growth for Bicycle,” said Kevin Lee, Ph.D., Chief Executive Officer of Bicycle Therapeutics. “Cancer Research UK has identified a recommended dose, which is within the therapeutic range predicted by preclinical models, for the Phase IIa study of BT1718, which we expect to commence this year. Our next-generation Bicycle Toxin Conjugates (BTCs), BT5528 and BT8009, are quickly progressing through respective stages of development. In addition, we believe our recently announced early discovery collaboration with Genentech will allow us to make considerable investments in expanding our portfolio of immuno-oncology assets, including our wholly-owned programs nearing late preclinical development. Beyond oncology, we continue to make progress on our partnered programs and to execute on our strategy of leveraging our collaborators’ expertise in specific therapeutic areas to advance the development of Bicycle-based medicines across a broad range of serious diseases.”

Dr. Lee continued: “While we expect that the evolving COVID-19 pandemic may impact the pace of clinical development, at this time, we believe the strong progress we’ve achieved across our pipeline to date will enable us to reach our anticipated 2020 milestones as planned.”

BT1718, a potential first-in-class BTC targeting key tumor antigen MT1-MMP

  • Cancer Research UK Completed Phase I Dose Escalation of BT1718 in Patients with Solid Tumors, Established Recommended Phase II Dose (RP2D) at 20 mg/m2. The key objectives were met in a Phase I dose escalation sponsored by Cancer Research UK and evaluating safety and tolerability of BT1718 in an unselected group of patients with advanced solid tumors. Based on study results, Cancer Research UK established an RP2D for the expansion cohorts at 20 mg/m2 administered once weekly. This recommended dose is within the efficacious dose range predicted by preclinical models, in which an equivalent dose level was associated with complete responses. With once-weekly dosing, BT1718 appeared tolerable, with manageable adverse events.

    Though not a key objective of the Phase I portion of the Phase I/IIa study, preliminary signs of anti-tumor activity were observed during the dose escalation. As reported at the European Society of Medical Oncology (ESMO) 2019 Annual Congress, 13 of 24 evaluable patients (54%) had stable disease at the eight-week timepoint, including a patient who experienced a 45% reduction in a target lesion, with findings generally remaining consistent as the trial progressed. Today, Bicycle announced that, in addition, one patient with small cell lung cancer experienced a partial response, with a 68% reduction in a target lesion.

    The Company anticipates that Cancer Research UK will initiate the Phase IIa portion of the Phase I/IIa study of BT1718 in 2020, although timing may be